Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents. Successful treatment of children with RMS requires multimodal therapy. However, despite advances in combined chemotherapy, radiation therapy and surgery, children with stage IV RMS have a uniformly poor outcome.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents. Successful treatment of children with RMS requires multimodal therapy. However, despite advances in combined chemotherapy, radiation therapy and surgery, children with stage IV RMS have a uniformly poor outcome. 1 In case of nonembryonal histology in combination with metastatic involvement in three or more organ systems, the prognosis is dismal (3-year survival 5%). 2 Other unfavourable risk factors include the age at diagnosis of more than 10 years, bone or BM metastases and RMS of the extremities. Patients with more than two of these risk factors have a 5-year survival of 9%. 3 Most patients achieve a remission after conventional therapy, but relapse is frequent, indicating persistence of minimal residual disease. 4 Although RMS is a chemosensitive disease, the benefits of high-dose chemotherapy followed by autologous haematopoietic stem cell rescue for children with stage IV or relapsed RMS are not clear because randomized trials comparing this treatment with standard chemotherapy are lacking. In a meta-analysis of 389 patients identified from 22 publications, there was no significant survival advantage of high-dose chemotherapy followed by autologous haematopoietic stem cell rescue for patients with relapsed or metastatic RMS as compared with standard chemotherapy. 5 GVL effect is well documented after allogeneic SCT for haematological malignancies. Recently, the evidence of graft-versus-tumour effect has also been described in patients with a variety of solid tumours. 6 Only sporadic cases have been reported of allogeneic SCT in high-risk RMS patients. Wiegel et al. 7 report on two children with relapsed stage IV RMS who received allogeneic SCT after a myeloablative regimen in a non-remission status. Both patients died of disease progression. However, outcome of patients with ALL is also poor when allogeneic SCT is performed in a non-remission status or in a status with high levels of minimal residual disease. 8 Misawa et al. describe a patient with refractory RMS for which an allogeneic SCT was performed after a myeloablative regimen. The patient reached a PR. As tumour regression occurred after the reduction of immunosuppressants on day þ 30, the authors suggest the existence of a graft-versus-tumour effect. However, 80 days after transplantation, disease progression occurred. On day 165, the patient died of progressive disease in the final stage accompanied by fungal pneumonia. 9 In this letter we report, a patient with stage IV RMS who achieved CR and is in ongoing remission for 4 years after combined therapy followed by allogeneic SCT.
An 8-year-old Caucasian girl was diagnosed with an alveolar RMS of the right gastrocnemical muscle (Figure 1 ). PAX-3 and PAX-7 fusion genes, which are specific for alveolar RMS were detected by reverse-transcription PCR. Staging revealed stage IV with extensive local, abdominal and thoracic lymph node metastases in combination with skeletal metastases (Figure 2 imaging showed a good response of the tumours. Because of the extensive disease at diagnosis, local therapy consisting of radiation to all involved areas was considered unacceptably toxic. As an alternative strategy, allogeneic SCT was proposed, on the basis of the principle of a possible graft-versus-tumour effect. Imaging showed a CR prior to transplantation. Pre-transplant conditioning consisted of etoposide at a dose of 350 mg/m 2 once daily intravenously on days À9 and À8, CY of 60 mg/kg once daily intravenously on days À5 and À4 and TBI at a dose of 7.5 Gy on day À2. On day 0, the patient received BM containing 8.2 Â 10 6 /kg CD34 þ cells from an HLAidentical sibling donor. T-cell depletion was not performed. CsA was administered as GVHD prophylaxis and was continued until 6 months after transplantation. Haematopoietic reconstitution was achieved on day þ 20 (reticulocytes 45 promille). Besides a subtle rash on the skin, there were no signs of acute GVHD. The patient is in ongoing CR now for 4 years. The tubulopathy has evolved into severe chronic renal insufficiency (glomerulae filtration rate (GFR) of 29 ml/min per 1.73 m 2 according to Schwartz formula, reference range 55-135 ml/min per 1.73 m 2 ). However, the situation is stable with conservative treatment, and renal function replacement therapy seems not to be necessary in the near future.
Patients with relapsed or metastatic RMS have an extremely poor prognosis. As there is no evidence to support the use of high-dose chemotherapy followed by autologous haematopoietic stem cell rescue, allogeneic SCT is currently discussed as a therapeutic option for high-risk RMS. 5, 6 In a non-remission status, the results are still disappointing. 7, 9 We performed a successful allogeneic SCT in a patient with stage IV RMS in CR. Under the limitation that our data are based on only one patient, we suggest the existence of a graft-versus-tumour effect in RMS.
Although further investigation is required, allogeneic SCT could provide a new therapeutic option for high-risk RMS. As the pre-transplantation chemotherapy in RMS is different from the regimen in haematological malignancies and consists of highly nephrotoxic drugs, attention has to be paid to define the most optimal conditioning prior to transplantation to achieve maximal survival and minimal late effects. 
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